Humana (NYSE:HUM) Given New $370.00 Price Target at Oppenheimer

Humana (NYSE:HUM) had its target price lowered by equities researchers at Oppenheimer from $415.00 to $370.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the insurance provider’s stock. Oppenheimer’s price target points to a potential upside of 17.07% from the stock’s current price.

Other research analysts have also issued research reports about the company. TheStreet lowered Humana from a “b” rating to a “c+” rating in a research report on Monday, January 8th. Deutsche Bank Aktiengesellschaft lowered Humana from a “buy” rating to a “hold” rating and decreased their target price for the company from $595.00 to $360.00 in a research report on Thursday, January 25th. Bank of America reiterated a “neutral” rating and set a $342.00 target price (down previously from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. UBS Group reissued a “neutral” rating and issued a $370.00 price objective (down from $530.00) on shares of Humana in a research note on Friday, January 26th. Finally, Wells Fargo & Company reduced their price objective on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research note on Monday, April 8th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Humana has an average rating of “Hold” and an average price target of $440.95.

Humana Trading Down 3.6 %

Humana stock opened at $316.04 on Thursday. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63. Humana has a 12 month low of $299.23 and a 12 month high of $541.21. The stock’s 50 day simple moving average is $329.24 and its two-hundred day simple moving average is $396.94. The firm has a market cap of $38.13 billion, a PE ratio of 15.95, a P/E/G ratio of 1.92 and a beta of 0.45.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a return on equity of 19.44% and a net margin of 2.34%. The business had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the prior year, the firm posted $9.38 EPS. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. Analysts anticipate that Humana will post 16.06 earnings per share for the current year.

Insider Buying and Selling

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was purchased at an average cost of $367.09 per share, with a total value of $200,064.05. Following the transaction, the director now owns 2,578 shares of the company’s stock, valued at $946,358.02. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.32% of the company’s stock.

Hedge Funds Weigh In On Humana

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley boosted its holdings in Humana by 6.2% during the 3rd quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock valued at $992,938,000 after acquiring an additional 119,760 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Humana by 35.9% during the third quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock worth $741,409,000 after buying an additional 402,559 shares during the period. Norges Bank acquired a new stake in Humana in the fourth quarter valued at approximately $676,800,000. Northern Trust Corp increased its position in shares of Humana by 5.1% in the 3rd quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock valued at $645,850,000 after purchasing an additional 64,245 shares during the last quarter. Finally, Sanders Capital LLC purchased a new stake in shares of Humana during the 4th quarter worth $489,300,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.